Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Affordable CAR-T breakthrough: academic therapy offers new hope for blood cancer patients

NCT ID NCT07524816

Recruiting now Disease control Sponsor: N.N. Alexandrov National Cancer Centre Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated Jun 16, 2026 · Updated 11 times

Summary

This study is testing a more affordable version of CAR-T cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The treatment uses the patient's own immune cells, modified to attack cancer cells. The goal is to see if this academic-made therapy works as well as expensive commercial versions, making it more accessible to patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NN Alexandrov National Cancer Centre of Belarus

    RECRUITING

    Lyasny, Minsk Oblast, 223040, Belarus

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA (LBCL) LARGE B-CELL LYMPHOMA (LBCL)